We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
How to buy Zykadia:
You can order Zykadia (ceritinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Mode of Action
Kinase inhibitor (targeted therapy)
EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Who is ceritinib for?
Zykadia (ceritinib) is indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) . While the FDA and EMA recommend it for first-line treatment , the TGA recommend it for patients whose disease has progressed on, or who are intolerant of crizotinib .
Complete information about Zykadia (ceritinib) dosage and administration can be found here: . The standard dosage is:
750 mg (5 capsules) orally once daily.
Taken at least 1 hour before or at least 2 hours after a meal.
Consult your treating doctor for personalised dosing.
What is ceritinib and how does it work?
Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with metastatic ALK-positive NSCLC . Mutations of the ALK gene can occur in several different types of cells, including lung cells, and can result in the development of a tumour . ALK gene mutations occur in 2 to 7 % of patients with NSCLC . Ceritinib is an ALK-inhibitor, which acts by inhibiting the activity of the ALK protein, and may thus prevent ALK-positive NSCLC-cells from growing and spreading .
What is ceritinib's approval status?
Zykadia (ceritinib) was approved by:
FDA (USA) on April 4, 2014  with an accelerated approval for ALK-positive NSCLC in patients whose disease has progressed on or who are intolerant of crizotinib; and on May 26, 2017  with regular approval for previously untreated ALK-positive metastatic NSCLC
as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The EMA and TGA approvals of ceritinib for ALK-positive NSCLC in previously treated patients were based on two main global, multicentre, open-label, single-arm studies (study X2101 and study A2201) which involved in total 303 patients in whom the disease progressed despite previous treatment with crizotinib (Xalkori). In both studies, the medicine was not compared with any other treatment. The overall response rate (ORR) was 56.4 % [95 % CI: 48.5, 64.2] in Study X2101 and 37.1 % [95 % CI: 29.1, 45.7] in study A2201. The median duration of response (DoR) was 8.3 months [95 % CI: 6.8, 9.7] in Study X2101 and 9.2 months [95 % CI: 5.6, NE] in study A2201. The median progression-free survival (PFS) was 6.9 months [95 % CI: 5.6, 8.7] in Study X2101 and 5.7 months [95 % CI: 5.3, 7.4] in study A2201 . The FDA and EMA approval of ceritinib for ALK-positive NSCLC in previously untreated patients was based on an open-label, randomized, active-controlled multicenterStudy (ASCEND-4) involving 376 previously untreated ALK-positive NSCLC patients who were treated with Zykadia (ceritinib) or chemotherapy. The median PFS was 16.6 months [95 % CI: 12.6, 27.2] in the ceritinib arm and 8.1 months [95 % CI: 5.8, 11.1] in the chemotherapy arm. The ORR, was 73 % [95 % CI: 66, 79] and 27 % (95 % CI: 21, 34) in the ceritinib and chemotherapy arms, respectively. The median DoR was 23.9 months [95 % CI: 16.6, not estimable] and 11.1 months [95 % CI: 7.8, 16.4] in the ceritinib and chemotherapy arms, respectively. In patients with measurable central nervous system (CNS) lesions on baseline brain scans, the confirmed overall intracranial response rate (OIRR) was 57 % [95 % CI: 37, 76] in the ceritinib arm and 22 % [95 % CI 9, 42] in the chemotherapy arm. The median CNS response duration was 16.6 months [95 % CI: 8.1, NE] and not estimable [95 % CI: 1.5, NE] in the ceritinib and chemotherapy arms, respectively .
Buyer There is a 6% tax on medicines + 21% tax on shipping for EU individuals
Shipping Cost Estimate
*Once you provide us with the exact shipping address, the actual price may vary.
Send this price estimate to your email address
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions